Search

PhagoMed has announced it will develop a phage lysin for bacterial vaginosis (targeting Gardnerella vaginalis). This means the company is extending its portfolio, as prior to this it was only working on complete phages. Press Release | News

PhagoMed has announced it will develop a phage lysin for bacterial vaginosis (targeting Gardnerella vaginalis). This means the company is extending its portfolio, as prior to this it was only working on complete phages. Press Release | News

I have a master's degree in microbiology. I defended my thesis with the title of 'Isolation and Identification of Specific Viruses Isolated from the Microbial Corroded Place in the Petroleum Industry' with the best grade. The title of one o

I have a master's degree in microbiology. I defended my thesis with the title of 'Isolation and Identification of Specific Viruses Isolated from the Microbial Corroded Place in the Petroleum Industry' with the best grade. The title of one o

The phage biotech company BiomX has presented in vivo data that shows successful intra-tumoural delivery of phages to Fusobacterium nucleatum, bacteria that reside inside tumours and whose presence is thought to protect tumours from chemoth

The phage biotech company BiomX has presented in vivo data that shows successful intra-tumoural delivery of phages to Fusobacterium nucleatum, bacteria that reside inside tumours and whose presence is thought to protect tumours from chemoth

Armata Pharmaceuticals has developed a new synthetic phage candidate targeting P. aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The cocktail, a mixture of synthetic and natural phages, has

Armata Pharmaceuticals has developed a new synthetic phage candidate targeting P. aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients. The cocktail, a mixture of synthetic and natural phages, has

Polish company Proteon Pharmaceuticals has been awarded a 2.9 million Euro grant from the European Regional Development Fund to develop phages to fight bacterial infections in fish farming (aquaculture). The grant will help Proteon improve

Polish company Proteon Pharmaceuticals has been awarded a 2.9 million Euro grant from the European Regional Development Fund to develop phages to fight bacterial infections in fish farming (aquaculture). The grant will help Proteon improve

A&P Inphatec, LLC is commercializing the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source of the problem – giving wine growers an organic and su

A&P Inphatec, LLC is commercializing the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source of the problem – giving wine growers an organic and su

BiomX, a biotech company developing natural and engineered phages to treat microbiome diseases, announced a merger agreement with Chardan Healthcare Acquisition Corp. The combined company is expected to be listed on the New York Stock Excha

Dr. Joey Talbert The Talbert Research Group in the Department of Food Science & Human Nutrition at Iowa State University seeks a Postdoctoral Research Associate to join a multidisciplinary group focused on protein chemistry and enzyme techn

Dr. Joey Talbert The Talbert Research Group in the Department of Food Science & Human Nutrition at Iowa State University seeks a Postdoctoral Research Associate to join a multidisciplinary group focused on protein chemistry and enzyme techn

BiomX, a biotech company developing natural and engineered phages to treat microbiome diseases, announced a merger agreement with Chardan Healthcare Acquisition Corp. The combined company is expected to be listed on the New York Stock Excha

##### Call for Posters for Phage Futures Europe, Brussels, September 25-26 Looking to showcase your recent work to the phage therapy community? Phage Futures Europe is accepting abstract submissions for poster presentations. Your poster wil

PhagoMed, an Austrian phage therapy company, announced this week that it’s received 1.5 million Euro in additional investment!

PhagoMed, an Austrian phage therapy company, announced this week that it’s received 1.5 million Euro in additional investment!

##### Call for Posters for Phage Futures Europe, Brussels, September 25-26 Looking to showcase your recent work to the phage therapy community? Phage Futures Europe is accepting abstract submissions for poster presentations. Your poster wil